Effective January 1, 2025: ASP+6% reimbursement for EXPAREL when billing with code J0666 across all outpatient surgical settings.

ADVANCING POSTSURGICAL PAIN MANAGEMENT AND RECOVERY

Long-lasting pain control through the critical first few days after surgery to enhance patient recovery.¹

EXPAREL works locally at the surgical site and uses the proprietary multivesicular liposome (pMVL) technology, which encapsulates bupivacaine in a suspension of multivesicular liposomes. After injection, bupivacaine is released over time.² Learn more

More than

15 million patients

have received EXPAREL since 2012.

NOPAIN Act
(January 1, 2025)

Federal mandate requiring Medicare reimbursement for non-opioids like EXPAREL²

Stay informed
Latest
Indication

EXPAREL is approved for use in sciatic nerve block in the popliteal fossa and adductor canal block

Learn more
Join the Surgeon
Selector

Help patients looking for EXPAREL find you!

Sign up today
Interactive Block
Visualizer

Explore all the uses and site locations for EXPAREL

Explore now

NOPAIN, Non-Opioids Prevent Addiction in the Nation.

Important Notice

This site is intended to provide medical and product information to health care professionals in the United States.
To report an adverse event, email drugsafety@pacira.com or call 1-855-793-9727.
For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-793-9727.
These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.

Indication

EXPAREL^® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.
Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via nerve block were nausea, pyrexia, headache, and constipation.
Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia.
Do not admix lidocaine or other non-bupivacaine local anesthetics with EXPAREL. EXPAREL may be administered at least 20 minutes or more following local administration of lidocaine.
EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for nerve blocks, and/or pregnant patients.
Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.
EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block, or intravascular or intra-articular use.
The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.
Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.
Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.
Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.
Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Please refer to full Prescribing Information.

References

Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54(12):1552-1559.
Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCI for postsurgical analgesia in total knee arthroplasty. Knee. 2012;19(5):530-536.

SEE MORE

Events

Specialty

-

-

Click here to access nursing page

Anesthesia

Bariatric Surgery

Breast Surgery

Colorectal/General Surgery

Nursing

Obstetrics/Gynecologic Surgery

Oral/Maxillofacial Surgery

Orthopedic Surgery

Pediatric Surgery

Plastic Surgery

Spine Surgery

ADVANCING POSTSURGICAL PAIN MANAGEMENT AND RECOVERY

15 million patients

NOPAIN Act
(January 1, 2025)

Latest
Indication

Join the Surgeon
Selector

Interactive Block
Visualizer

Important Notice

Indication

Important Safety Information

Warnings and Precautions Specific to EXPAREL

Warnings and Precautions for Bupivacaine-Containing Products

References

Specialty

-

-

Click here to access nursing page

Anesthesia

Bariatric Surgery

Breast Surgery

Colorectal/General Surgery

Nursing

Obstetrics/Gynecologic Surgery

Oral/Maxillofacial Surgery

Orthopedic Surgery

Pediatric Surgery

Plastic Surgery

Spine Surgery

ADVANCING POSTSURGICAL PAIN MANAGEMENT AND RECOVERY

15 million patients

NOPAIN Act (January 1, 2025)

Latest Indication

Join the Surgeon Selector

Interactive Block Visualizer

Important Notice

Indication

Important Safety Information

Warnings and Precautions Specific to EXPAREL

Warnings and Precautions for Bupivacaine-Containing Products

References

NOPAIN Act
(January 1, 2025)

Latest
Indication

Join the Surgeon
Selector

Interactive Block
Visualizer